Biotech Strategy Blog
Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy
-
The most interesting number in Tango’s data isn’t 92%
-
On a wing and a prayer
-
When KRAS resistance isn’t the end of the story
-
ASCO26 HARMONi6 Updated – Plaudits, Pitfalls, and Pratfalls
-
On KRAS inhibitors and why potency doesn’t equal durability
-
Six ASCO trials decoded: Data, Gaps, and Implications
-
Cat amongst the pigeons
-
Reflections on potentially practice changing trials
-
What if the first target was the problem?
-
Late line RCC: where darlifarnib fits and why LITESPARK-012 matters
-
Pointed ironies: SERD wars, ADC hype, and what really works in breast cancer
-
A bear thesis – why HARMONi-6 won’t replicate globally